Independent Review Consulting (IRC) and the Ethical Review Committee (ERC), both Independent Institutional Review Boards (IRB) representing nearly 50 years of combined service to the research industry are pleased to announce the finalization of their merger agreement.
While the individual boards of each company will continue their review of existing projects respectively, all new submissions of business will be accepted and managed by Ethical and Independent Review Services, LLC (E&I). E&I will offer review of research by an AAHRPP accredited board in California. A second board in the Midwest anticipates receipt of accreditation in the coming months.
Services offered through E&I will include reviews of both private and federally funded research, training and consulting services, and the development of more specialized review boards. Both companies are excited by this opportunity to provide a larger spectrum of review services and a greater base of experience from which they can support their human subject protection program.
Both companies have experience in the review of late-stage, multi-center trials. While IRC specializes in medical devices and federally funded studies, ERC has developed processes specializing in efficient turn-around of large, late-stage multi-center trials.
An E&I Review Services website, with automated forms, will be available at completion of merger, anticipated in coming weeks.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.